Physician Office Labs At Cholestech’s Fingertips: CRP, Waived Tests In Reach
This article was originally published in The Gray Sheet
Executive Summary
Cholestech will conduct clinical studies to support Medicare reimbursement for Endo-Pat 2000, a device that measures vascular endothelial dysfunction, an early-stage marker of atherosclerosis
You may also be interested in...
CRP Coronary Disease Test Value Challenged By Icelandic Study – NEJM
C-reactive protein diagnostics offered little diagnostic benefit for coronary disease detection in a large prospective Icelandic study published in the April 1 New England Journal of Medicine.
Itamar Pursuing Sleep Apnea As First Application Of PAT Platform
Respironics will distribute Itamar Medical's peripheral arterial tonometry technology (PAT) with its sleep monitoring instruments to assist in the diagnosis of sleep apnea.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.